FGFR3::BAIAP2L1
About
Biomarker Type: Rearrangement
Present: True
Rearrangement Type: Fusion
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | FGFR3::BAIAP2L1 | Bladder Urothelial Carcinoma | Erdafitinib |